Diamant, Eugenie A. P. Kuijpers, Jacob K. Sont, and Peter J. Sterk. Role of neutral endopeptidase in exercise-induced bronchoconstriction in asthmatic subjects. J. AppZ. Physiol. 81(2): 673-678, 1996.-The membrane-bound metalloproteinase, neutral endopeptidase (NEP), is a degrading enzyme of both bronchoconstrictor and bronchodilator peptides within the airways. To examine the role of NEP in exercise-induced bronchoconstriction (EIB) in asthmatic subjects, we used inhaled thiorphan, a NEP inhibitor, as pretreatment to a 6-min standardized exercise challenge. Thirteen clinically stable asthmatic subjects participated in this double-blind, placebo-controlled, crossover study that was performed on 2 days separated by 48 h. Thiorphan was administered by two inhalations of 0.5 ml containing 1.25 mg/ml. Subsequently, exercise was performed on a bicycle ergometer at 40-50% of predicted maximal voluntary ventilation while inhaling dry air (20°C, relative humidity 6%). The airway response to exercise was measured by forced expiratory volume in 1 s (FE&) every 3 min, up to 30 min postexercise challenge, and was expressed both as the maximal percent fall in FE& from baseline and as the area under the time-response curve (AUC) (O-30 min). The acute effects of both pretreatments on baseline FE& were not different (P > 0.2), neither was there any difference in maximal percent fall in FE& between thiorphan and placebo (P > 0.7). However, compared with placebo, thiorphan reduced the AUC by, on average, 26% [AUC (O-30 min, +SE): 213.6 t 47.7 (thiorphan) and 288.6 t 46.0%fallh (placebo); P = 0.0471. These data indicate that NEP inhibition by thiorphan reduces EIB during the recovery period. This suggests that bronchodilator NEP substrates, such as vasoactive intestinal polypeptide or atria1 natriuretic peptide, modulate EIB in patients with asthma. asthma; membrane metallo-endopeptidase; neuropeptides; natriuretic peptides, atrial; thiorphan.
NEUTRAL ENDOPEPTIDASE (NEP; EC 3.4.24.11) is a glycosylated zinc-dependent membrane-bound metalloproteinase with a broad selectivity, which preferentially cleaves peptides on the amino side of hydrophobic residues (29). In the lungs of different animal species and humans, NEP has been localized in the basal cells of the epithelium, alveolar type II cells, submucosal glands, airway smooth muscle, postcapillary venules, and nerves (1819).
NEP can be considered as a potential modulator of airway obstruction, which might be particularly relevant in diseases like asthma (23). Inhibition of NEP by inhaled thiorphan or phosphoramidon has been reported to be ineffective in changing baseline lung function or bronchial hyperresponsiveness to methacholine in both normal and asthmatic subjects in vivo (10, 11). Therefore, in mild and stable asthma, NEP substrates do not seem to be involved in the maintenance of airway patency. However, the potential role of NEP and its substrates during the development and recovery of acute airway obstruction, e.g., induced by a physiological challenge such as exercise, has not been elicited.
Standardized exercise challenges (31) are able to provoke bronchoconstriction in 7080% of the asthmatic subjects, as reflected by a X5% fall in forced expiratory volume in 1 s (FE&). The major determinant for the severity of exercise-induced bronchoconstriction (EIB) is the level bfventilation during exercise (1). There is little doubt that water loss resulting in a transient hyperosmolarity and/or cooling of the airways is the physical stimulus for EIB, resulting in contraction of airway smooth muscle, vasodilation, and airway wall edema (1). As appears from in vitro and in vivo studies in animals and in humans, both cellular pathways and neurogenic mechanisms are likely to be involved in EIB. Apart from mast cell-and/or eosinophilderived mediators (12, 22, 33) , there is growing evidence that after hyperosmolar and/or cold dry air stimulation neurogenic activity may contribute to the subsequent airway obstruction (21, 28, 32, 34) . These neural mechanisms particularly refer to nonadrenergic noncholinergic (NANC) pathways (28, 32, 34) , which can be either excitatory (eNANC), through NEP substrates such as substance P, neurokinin A (NKA), and calcitonin gene-related peptide, or inhibitory (iNANC) by, e.g., vasoactive intestinal polypeptide (VIP) and nitric oxide (NO) (4, 5, 8) . Finally, atria1 natriuretic peptide (ANP) is another NEP substrate (3) potentially inhibiting EIB, since plasma immunoreactive ANP levels have been shown to rise between 3 and 15 min postexercise (30).
Hence, the role of NEP in EIB can be bifunctional. First, the observation of an increase of hyperpneainduced bronchoconstriction in guinea pigs (28) and of hypertonic saline-induced vascular permeability in the rat trachea (32) after pretreatment with phosphoramidon indirectly favors the involvement of the eNANC system in EIB, thereby suggesting a potentially protective role of NEP in EIB. Alternatively, any activation of the iNANC system and the rise in ANP levels (30) during exercise would imply an aggravating role of NEP in EIB.
In this study, we addressed the above hypotheses by examining the effect of pretreatment with the inhaled NEP inhibitor thiorphan on the development and recovery of EIB in patients with asthma. (27), and all were hyperresponsive to histamine (provocative concentration of histamine causing a 20% fall in FE& <4 mg/ml) (31). All subjects reported symptoms of EIB, which were confirmed by a fall in FE& exceeding 15% from the baseline value after a 6-min exercise challenge at screening (Table 1) . There was no history of upper respiratory tract infection or relevant allergen exposure during the 2 wk before the start of the study. The subjects had not used corticosteroids, antihistamines, sodium cromoglycate, nedocromil sodium, or theophyllines for at least 6 mo before the study. Before testing, they were asked to refrain from inhaled short-acting bronchodilators for at least 8 h and from caffeine-containing beverages for at least 4 h. The protocol was approved by the Medical Ethics Committee of the Leiden University Hospital, and all participants gave their written informed consent.
Study design. On two screening days before the study, the inclusion criteria were examined for each subject. The study had a placebo-controlled crossover design and was performed on 2 days with an interval of 48 h. On both study days, an exercise challenge was performed 10 min after double-blind and randomized pretreatment with inhaled thiorphan or placebo. FE& was measured every 3 min up to 30 min after cessation of the exercise challenge. Afterward, aerosolized salbutamol was administered (200 ug per metered-dose inhaler). The variability in baseline FE& was not allowed to exceed 10% between both study days. Each subject attended the laboratory at the same time of day (22 h) on each study day. or placebo (normal saline containing 1% human serum albumin), was administered by using a method that has previously been shown to be safe and effective in humans (10, 11). Thiorphan was stored at -20°C and warmed up on melting ice before nebulization. The aerosols were generated by an efficient and previously validated jet nebulizer (Malinckrodt Diagnostica, Petten, The Netherlands) that is suitable for the administration of high doses of precious substances (10, 11). The dose of thiorphan was based on previous dose-finding experiments (11). The nebulizer was filled twice with 0.5 ml of the thiorphan solution (1.25 mg/ml), which was sprayed by compressed nitrogen during 1 min into a 30-liter collapsible drying chamber in which the droplets (saline mass median aerodynamic diameter 2.5 urn) rapidly evaporate to dry particles (mass median aerodynamic diameter 0.6 urn) (6). Subsequently, the aerosols, with a deposition fraction of -50% within the intrapulmonary airways (6), were inhaled through a three-way valve box and a mouthpiece by tidal breathing for 3-4 min each, with the nose clipped. Oxygen was supplied through the mouthpiece at a flow of 4 Vmin. Exercise challenge. The exercise challenge was performed according to a standardized protocol (31) with some modifications, using a bicycle ergometer.
The work intensity was selected for each individual subject to achieve a minute ventilation between 40 and 50% of his or her predicted maximal voluntary ventilation (35 X FE& predicted) during 6 min. Compressed dry air (20°C, relative humidity 6% H20) was administered through an air-supply bag connected to a Hans Rudolph three-way valve. The subject wore a face mask covering the nose and the mouth together with an noseclip to ensure mouth breathing of dry air alone. MethachoZine controZ experiments.
To exclude an effect of thiorphan on recovery from bronchoconstriction per se, placebo-controlled crossover control experiments were performed by using thiorphan or placebo as a pretreatment 10 min before methacholine challenge in eight asthmatic subjects who met the same inclusion requirements.
Methacholine challenge was performed according to a standardized procedure (31) by using methacholine (acetyl-Pmethylcholine bromide) (Sigma Chemical) in normal saline. Serial doubling concentrations ranging from 0.3 to 40 mmol/ml in normal saline were aerosolized with the use of a nebulizer (model 646; DeVilbiss, Somerset, PA) operated by oxygen (output 0.13 ml/ min) and connected to the central chamber of an inspiratory-expiratory valve box with an expiratory aerosol filter (Ultipor BB50; Pall, Portsmouth, UK). The aerosols were inhaled by tidal breathing for 2 min at 5-min intervals until FE& fell by X0% from baseline value. The subjects wore a noseclip during aerosol inhalation.
Airway responses to methacholine were measured by FE&. Before and immediately after thiorphan or placebo inhalation, three measurements of FE& were recorded to calculate mean baseline FE&. The mean value after pretreatment was used as the premethacholine baseline in the analysis. The recovery from the response to methacholine was measured every 3 min during 30 min following the challenge.
Andysis. The bronchoconstrictor response to exercise and methacholine were expressed as the maximal percent fall in FE& from the baseline value and as the AUC over the 30-min period postchallenge (AU&-30 min ). Student's paired t-test was applied to test the differences in those variables between thiorphan and placebo. Subsequently, Student's paired t-test was applied at the individual time points to explore the differences between thiorphan and placebo pretreatment at each specific time point. P values < 0.05 were considered statistically significant.
RESULTS
Safety. All subjects completed the study. Thiorphan was well tolerated in all subjects, and no reverse reactions occurred.
Exercise challenge. Baseline FE& before pretreatment was not different between both randomized study days (P > 0.3) ( Table 2) . Similarly, there was no difference in the change in FE& after thiorphan and placebo pretreatment (P > 0.2). Post-pretreatment FE& was not different between the two pretreatments (P > 0.8).
The mean time-response curves after placebo and thiorphan are shown in Fig. 1 . Exercise induced a maximal percent fall in FE& from baseline of 17.6 2 2.4 (SE)% after thiorphan and 18.1 2 2.1% after placebo pretreatment, respectively. There was no sign.ifi- cant difference in maximal percent fall in FE& between both pretreatments (P = 0.80).
However, when analyzed as AUC for the 30-min period, thiorphan significantly attenuated the bronchoconstrictor response to exercise by on average 26% compared with placebo (mean AUC t SE: 213.6 2 47.7 and 288.6 2 46.0%fall.h, respectively; P = 0.047) (Fig.  2) . On analyzing individual time points of the timeresponse curve, it appeared that this difference in AUC was predominantly due to the recovery period (15-30 min postexercise) (Fig. 1) .
Methacholine control experiments. In the separate experiments using methacholine challenge, there was also no difference in changes in baseline FEVl after 700 600 I placebo thiorphan and 275.4 t 53.0 for placebo; P = 0.5) (Fig. 3) .
DISCUSSION
The results of the present study show that, in patients with asthma, inhibition of NEP by inhaled thiorphan significantly attenuates the bronchoconstrictor response to exercise when expressed as AUC over a 30-min period postchallenge. This does not occur after methacholine-induced bronchoconstriction. These findings suggest that bronchodilator peptides, which are sensitive to degradation by NEP, exert a protective effect during the recovery period of EIB and that this effect is not due to bronchoconstriction per se. This is the first study examining the role of NEP and NEP substrates during EIB in asthmatic subjects in vivo. Previous animal experiments have addressed an analogous question by using hyperosmolar or cold/dry air as stimuli to the airways in vivo and in vitro. In guinea pigs, it has been reported that intravenously administered phosphoramidon, another NEP inhibitor, augmented the bronchoconstrictor response to isocapnit hyperpnea in vivo (28) and potentiated the increase of vascular permeability caused by hypertonic saline in vitro (32). Therefore, eNANC responses mediated by NEP substrates, such as substance P, NKA, and/or calcitonin gene-related peptide, seem to be involved in hypertonic saline-and hyperventilation-induced bronchoconstriction in guinea pigs. Because these physical stimuli are essentially those considered to be most prominent during exercise challenge, involvement of the eNANC system in human EIB might have been anticipated. Consequently, this would have implied a protective effect of NEP during EIB. Remarkably, however, our findings of the contrary argue against exerciseinduced eNANC activity in asthma.
In the present study, we examined the role of NEP activity during exercise challenge by using inhaled thiorphan as a pretreatment.
We believe that the observed effects of thiorphan can indeed be interpreted in terms of NEP inhibition, since the selectivity of thiorphan for NEP compared with, e.g., angiotensinconverting enzyme is 50-fold (29). In addition, it is unlikely that our findings can be explained by measurement errors, since the data have been obtained by means of validated methodology. First, the challenges were carried out in a standardized way (31), using dry air to increase the ventilatory stimulus to the airways. Second, we confirmed that inhalation of thiorphan per se failed to cause significant bronchodilation in normal as well as in asthmatic subjects in vivo (7, 10, 11). Cheung et al. (10) demonstrated that lung function does not change when comparing thiorphan and placebo up to 90 min postinhalation. Thus a direct bronchodilator effect cannot explain the improvement in FE& between 15 and 30 min after exercise in the present study. Furthermore, we used the same dose of thiorphan as has been shown to potentiate the bronchoconstrictor response to inhaled NKA in both nonasthmatic and asthmatic subjects (10, 11) and to inhaled metabisulfite in nonasthmatic subjects (7). Because potentiation of the latter challenge by thiorphan can be considered to be due to reduced breakdown of endogenous neuropeptides, it seems likely that the present dose of thiorphan has been sufficient to inhibit cleavage of NEP substrates released secondary to exercise challenge. To exclude an effect of thiorphan on recovery from bronchoconstriction per se, we performed control experiments using thiorphan as a pretreatment to methacholine challenge. We could not detect an effect of thiorphan on the recovery from methacholine-induced bronchoconstriction, thereby favoring a specific exerciseinduced release of bronchodilator NEP substrates in asthma. Finally, to exclude possible differences in NEP activity based on atopy or environmental factors, we selected a homogeneous group of nonsmoking, atopic, mildly-to-moderately asthmatic subjects without a history of viral infection and not using steroid medication before and during the experiments.
There are at least two mechanisms that could possibly account for the protective effect of NEP inhibition by inhaled thiorphan on EIB: namely, iNANC responses (4,s) and/or ANP (3, 25) . iNANC responses are mediated by the release of neuropeptides such as VIP and NO, potentially resulting in relaxation of airway smooth muscle (4). In contrast to VIP, NO is not sensitive for degradation by NEP (29), suggesting that VIP might be responsible for the reduction of EIB by inhaled thiorphan. Although it has been reported that VIP-positive nerve fibers are absent in lung tissue of severe asthmatic patients at autopsy (24) in bronchial biopsies of mildly asthmatic patients compared with nonasthmatic controls. Therefore, it cannot be excluded that diminished breakdown of VIP can be responsible for the attenuation of EIB in the subjects of the present study.
Apart from NEP, it has been shown that other enzymes, such as tryptase and chymase released from airway mast cells, are capable of rapidly degrading VIP (9). However, so far, this has not been confirmed in humans in vivo. Jarjour and Calhoun (17) could not demonstrate a change in histamine and tryptase levels in bronchoalveolar lavage fluid either shortly or 24 h after exercise challenge in patients with asthma. It can be argued that these assays may not have been sensitive enough to exclude the involvement of mast cell proteases in EIB. However, since it is unlikely that thiorphan affects tryptase or chymase enzyme activity, we believe that this metabolic pathway of VIP does not explain the present findings.
Inhibition of NEP by inhaled thiorphan might have had an indirect effect on NO synthesis, since interaction between VIP and NO has been described in smooth muscle of the gut (20). In several in vitro studies on human and animal gut smooth muscle cells, it has been shown that, apart from NO production in VIP-immunoreactive nerves, NO is mainly derived from muscle cells during nerve stimulation secondary to VIP activity (13). It can b e speculated that similar VIP-induced activation of NO-dependent pathways may also occur in smooth muscle tissues in other organs (20), so that NEP inhibition by thiorphan in the present study may have increased NO production secondary to inhibiting VIP breakdown in the airways. Particularly, since in healthy subjects increased NO production during exercise has been detected (26), this hypothesis requires further investigation, e.g., by measuring NO synthesis in exhaled air in asthma.
ANP is another bronchodilator peptide that is degraded and inactivated by NEP (29). Inhaled thiorphan has been shown to enhance the ANP-induced attenuation of the bronchoconstrictor response to histamine (3). Apart from its predominantly atria1 synthesis and release, ANP is also produced and stored in peripheral tissues such as the lung (14 
